Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
Fuqiang Wen Yanmin Wu Chunyan Xing Yingqun Zhu Yongxing Chen Xiaodong Mei Massimo Corradi Glauco Cappellini Emanuele Calabro Sergio Amodio Cissy Zhu Dmitry Galkin a Department of Respiratory and Critical Care Medicine,West China Hospital,Chengdu,Chinab Department of Respiratory and Critical Care Medicine,Xuzhou Central Hospital,Xuzhou,Chinac Department of Respiratory and Critical Care Medicine,Jinan Central Hospital,Jinan,Chinad Department of Respiratory and Critical Care Medicine,The Third Hospital of Changsha,Changsha,Chinae Department of Respiratory and Critical Care Medicine,Hainan Affiliated Hospital of Hainan Medical University,Hainan General Hospital,Haikou,Chinaf Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of USTC,University of Science and Technology of China,Hefei,Chinag Department of Medicine and Surgery,University of Parma,Parma,Italyh Global Clinical Development,Chiesi Farmaceutici SpA,Parma,Italyi Global Pharmacovigilance,Chiesi Farmaceutici SpA,Parma,Italyj Global Clinical Development,Chiesi Pharmaceutical Consulting (Shanghai) Co. Ltd,Shanghai,Chinak Global Clinical Development,Chiesi USA Inc,Cary,NC,USA
DOI: https://doi.org/10.1080/15412555.2024.2425157
2024-11-13
COPD Journal of Chronic Obstructive Pulmonary Disease
Abstract:The fixed-dose combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) delivered via pressurised metered-dose inhaler (pMDI) has demonstrated efficacy in chronic obstructive pulmonary disease (COPD), in studies predominantly conducted in Caucasian adults. The current study evaluated the efficacy and safety of BDP/FF pMDI in Chinese patients with COPD, as part of registration for COPD in China. This double-blind, double-dummy, randomised, parallel-group study was conducted in patients with COPD of Chinese ethnicity aged ≥40 years. After a 4-week open-label budesonide/formoterol fumarate (BUD/FF) run-in period, patients were randomised to BUD/FF or BDP/FF for 24 weeks. The primary objective was to demonstrate non-inferiority of BDP/FF to BUD/FF in terms of change from baseline in pre-dose morning forced expiratory volume in 1 sec (FEV 1 ) at Week 24 (i.e. the lower 95% CI limit of the difference was above the pre-defined non-inferiority margin of −0.07 L). Of 750 patients randomised (377 BDP/FF; 373 BUD/FF), 87.6% completed the study. The primary endpoint was met in both the per-protocol (adjusted mean difference −0.001 L [95% CI: −0.025, 0.022], non-inferiority p < 0.001) and intention-to-treat populations (–0.001 L [–0.024, 0.022]; non-inferiority p < 0.001). There were no statistically significant BDP/FF–BUD/FF differences for the secondary endpoints, and a similar proportion of patients had adverse events (BDP/FF, 51.7%; BUD/FF, 51.2%), with most mild/moderate in severity. In conclusion, BDP/FF pMDI was non-inferior to BUD/FF in terms of pre-dose morning FEV 1 , supported by a range of secondary endpoints. Both treatments were similarly tolerated. The study supports the use of BDP/FF pMDI in Chinese patients with COPD.
respiratory system